[曲美他嗪MB代谢疗法对缺血性心脏病和慢性心力衰竭患者的疗效与安全性评估]
[Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure].
作者信息
Gorbunova M L, Vilkova A V
机构信息
1Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia; 2Nizhny Novgorod Cardiac Surgery Center Corll, Nizhny Novgorod, Russia.
出版信息
Kardiologiia. 2016 Mar;56(3):67-72. doi: 10.18565/cardio.2016.3.67-72.
UNLABELLED
Study purpose - to assess clinical and hemodynamic parameters in patients with ischemic heart disease (IHD) with and without use of metabolic therapy with trimetazidine MB.
MATERIALS
Seventy four patients with IHD, 40 of whom in addition to the main therapy for 3 months received metabolic preparation trimetazidine MB.
RESULTS
Number of anginal attacks and inhalations of nitroglycerin significantly decreased and parameters of hemodynamics improved after 3 months in patients who received trimetazidine MB.
CONCLUSION
Long-term use of trimetazidine MB in patients with IHD is advisable.
未标注
研究目的——评估使用和未使用曲美他嗪MB进行代谢治疗的缺血性心脏病（IHD）患者的临床和血流动力学参数。
材料
74例IHD患者，其中40例除接受3个月的主要治疗外，还接受了代谢制剂曲美他嗪MB。
结果
接受曲美他嗪MB治疗的患者在3个月后心绞痛发作次数和硝酸甘油吸入量显著减少，血流动力学参数得到改善。
结论
IHD患者长期使用曲美他嗪MB是可取的。
Zotero 插件